Replies to post #126852 on Biotech Values

[mcbio]

The results of litigation would be as such. Could be if given enough time they could work around patents. Look at HCV I think what was Chiron has a small royalty on just about every compound. I don't know what their patent is but just about everyone licenses it.

Sorry, I completely botched the interpretation of your prior post. ; ) I thought you worded it saying MNTA wanted that type of outcome.